Metabolic activity of primary tumour on PET/CT has a relationship with survival in stages I ‐III small‐cell lung carcinoma

ConclusionPretreatment SUVmax‐PT (median cut‐off 11.6) may have a prognostic value of OS and PFS in patients with TNM staged I‐III SCLC.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Immune checkpoint inhibitors (ICIs) are currently used as monotherapy or combination therapy in frontline and subsequent lines for metastatic lung cancer including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer (SCLC) [1 –5]. Furthermore, ICIs before or after surgery showed efficacy in patients with resectable disease, highlighting the potential of ICIs to improve outcomes in these patients and expand the use of ICIs in the neoadjuvant and adjuvant settings [6,7]. Despite higher response rates, longer duration of response, and less toxicity of ICIs compared with chemotherapy, many lung cancer pat...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Lung cancer is the leading cause of cancer-related deaths mainly attributable to metastasis, especially extrathoracic metastasis. This large-cohort research is aimed to explore metastatic profiles in different histological types of lung cancer, as well as to assess clinicopathological and survival significance of diverse metastatic lesions. Lung cancer cases were extracted and enrolled from the Surveillance, Epidemiology, and End Results (SEER) database. χ2-tests were conducted to make comparisons of metastatic distribution among different histological types and odds ratios were calculated to analyze co-occurrence rela...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
High-grade pulmonary neuroendocrine tumors, including small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), represent approximately 20% of primary lung tumors and predominantly affect older patients with a smoking history [1]. Both tumor types have a poor prognosis, with limited effective available therapies. Novel therapeutic options are urgently needed to alter the natural disease course and improve survival outcomes.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Among this large cohort, our center seems to follow the global trend with increasing incidence of ADC. EGFR mutation positivity was similar to existing reports, while higher ALK positivity was detected. A characteristic phenotype of never-smokers with lung cancer was elucidated which demonstrated better survival.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
Neuroendocrine (NE) tumors of the lung comprise four distinct histologic types: typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma (SCLC), as listed in the 2015 World Health Organization (WHO) classification of tumors of the lung, pleura, thymus and heart [1]. Although these four tumor types are grouped into the same category, PC (TC and AC) is not an early progenitor lesion of LCNEC or SCLC [2]. PC has distinct epidemiologic, clinical, histological, and genetic characteristics, and its incidence is not associated with cigarette smoking.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionThis is the first report of “real-world” data on ICI in relapsed SCLC also including patients with poor PS. Promising durable responses were observed. No biological prognostic marker could be identified.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant activation of kinase signaling and occur in ∼15% of non-small cell lung cancers (NSCLC). Patients diagnosed with EGFR-mutant NSCLC have good initial clinical response to EGFR tyrosine kinase inhibitors (EGFR TKIs), yet tumor recurrence is common and quick to develop. Mechanisms of acquired resistance to EGFR TKIs have been studied extensively over the past decade. Great progress has been made in understanding two major routes of therapeutic failure: additional genomic alterations in the EGFR gene and activation of alternative kin...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
ConclusionPre ‐treatment SUVmax‐PT (median cut‐off 11.6) may have a prognostic value of OS and PFS in patients with TNM staged I‐III SCLC.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsThis prospective study presents evidences for the diagnostic and prognostic capabilities of expression changes inCAPN8-2, TMC5 andMUC1 in LUAD, while they are non-significant in SCLC and lSCC. Their translation to clinical practice is proposed.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
AbstractASCL1 is one of the master transcription factors of small cell lung carcinoma (SCLC). To investigate the significance of ASCL1 in pulmonary neuroendocrine carcinoma, we performed 2 comparative RNA-seq studies between H69 (ASCL1-positive, classical type SCLC) and H69AR (ASCL1-negative, variant type SCLC) and betweenASCL1-transfected A549 adenocarcinoma cell lines (A549(ASCL1+) cell lines) and A549(control) cell lines. RNA-seq analyses revealed that 940 genes were significantly different between the H69 and H69AR cell lines, and 728 between the A549(ASCL1+) and A549(control) cell lines. In total, 120 common genes bet...
Source: Histochemistry and Cell Biology - Category: Biomedical Science Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Respiratory Medicine | Small Cell Lung Cancer | Study